** Shares of drug developer Disc Medicine rise ~28.6% to $60.60, highest since March
** Co says the FDA gave positive feedback supporting the design of a trial that will evaluate its genetic disorder drug bitopertin
** Bitopertin is being developed for the treatment of Erythropoietic protoporphyria $(EPP.UK)$, a rare inherited metabolic disorder
** IRON says the drug has potential for FDA's accelerated approval based on existing data
** "Improved approval timelines and clarification of confirmatory trial design are significant positives to IRON shares," says BMO Capital Markets
** Stock up 15.1% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。